- Home
- / Gene Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Gene Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-14
Market Capitalization
$6.5 K
2024-10-14
Revenue
$109.2 K
FY, 2013
CreditSafe Score
?
Score changed on Jun 12, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2019 | FY, 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 785.3K | 109.2K | ||||||
| Cost of goods sold | 437.1K | 69.2K | ||||||
| Gross profit | 348.3K | 40.0K | ||||||
| Gross profit margin, % | 44.3% | 36.7% | ||||||
| General and administrative expense | 4.8M | 6.1M | 4.9M | 2.9M | 2.8M | 2.2M | 593.5K | 1.0M |
| Operating expense total | 7.4M | 8.7M | 6.9M | 3.6M | 3.1M | 2.8M | 837.0K | 1.3M |
| EBIT | (7.4M) | (8.4M) | (6.9M) | (3.6M) | (3.1M) | (2.8M) | (837.0K) | (1.3M) |
| EBIT margin, % | -1068.3% | -6324.4% | ||||||
| Interest income | 11.2K | 6.6K | 217.0 | |||||
| Interest expense | 5.5K | 4.2K | 771.0 | 94.6K | 82.6K | 172.8K | 43.8K | 57.4K |
| Income tax expense | (4.4M) | (1.5M) | (9.1M) | (1.5M) | (305.7K) | |||
| Net Income | (7.1M) | (8.3M) | (8.9M) | (5.5M) | (3.7M) | (3.0M) | 779.1K | (651.5K) |
| EPS | 0.1 |